Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price was up 4% on Wednesday . The company traded as high as $8.15 and last traded at $8.01, with a volume of 89,860 shares traded. The stock had previously closed at $7.70.

A number of equities analysts have recently weighed in on AQXP shares. Needham & Company LLC started coverage on Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They set a “buy” rating and a $25.00 target price on the stock. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $19.86.

The company’s market capitalization is $141.65 million. The company’s 50 day moving average price is $7.13 and its 200-day moving average price is $8.55.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. On average, equities research analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($1.79) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc, formerly Aquinox Pharmaceuticals (USA) Inc, is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc is a wholly owned subsidiary of the Company.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.